22
Aug
2019

BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund
Merck Snaps Up New Cancer Drug, Denali Grows Up, & Gilead’s TCE Wager
Servier Buys Day One, Vertex Hits IgAN Phase III, & Prasad’s Unceremonious Exit at FDA